As price pressure intensifies in crowded therapy areas, healthcare systems are increasingly reliant on the introduction of generics and biosimilars in order to reduce spending. In this research, we test if physicians’ price sensitivity is sufficient to drive cost reductions alone, or if payer-led controls and guidelines must be implemented to effect this change.
Navigating the evolving landscape for psychedelic therapies
These substances may offer innovative treatment options for psychiatric conditions including PTSD, major and treatment-resistant depression, generalized...